iTonic Holdings Ltd Annual Report - How They Did This Year

I’ve put together this guide to help you understand how iTonic Holdings performed this year. My goal is to break down their complex filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

iTonic Holdings is a Cayman Islands company that operates through its Chinese subsidiary, Beijing Feitian. Their main product is FTTPS, a software system that helps doctors map radiation doses for cancer patients. They make money by selling software licenses and maintenance services to Chinese hospitals. They are also trying to enter the U.S. market with an AI-powered home care system, though this project is currently in the research phase and has not yet generated revenue.

2. Financial performance: The losses are growing

The 2025 results show a challenging trend:

• Revenue: They brought in $523,031, up from $448,196 in 2024. While this is a 16.7% increase, it is not enough to cover their basic operating costs.
• Profit/Loss: The company is losing money at an accelerating rate. They reported a $5.1 million loss in 2025, compared to a $660,588 loss in 2024. This 672% jump in annual losses is largely driven by higher administrative costs and spending on their unproven AI project.

3. Major wins and challenges

• The "Concentration" Trap: Two clients provided over 50% of their total revenue. If they lose even one of these contracts, the company’s revenue could drop by 25% or more.
• Nasdaq Trouble: In October 2025, Nasdaq warned the company that its stock price had stayed below $1.00 for too long. They have until April 2026 to address this, which may involve a reverse stock split—a move that often puts downward pressure on share prices.
• Dilution: In March 2026, the company issued 100 million new shares to raise $20 million. Because these were sold at a 51.7% discount to the market price, the ownership percentage of existing shareholders was significantly reduced.

4. Financial health and "The Fine Print"

• Accounting Gaps: Management has noted a lack of staff experienced in U.S. accounting rules, which increases the risk of financial reporting errors.
• Cash Flow: The company faces long payment cycles, often waiting 12 to 24 months to collect from hospitals. With $1.4 million in cash and a burn rate of $425,000 per month, their runway is limited.
• No Safety Net: The company carries no business insurance. Any potential legal liability resulting from a software-related medical error could pose a significant threat to their financial stability.

5. Key Risks: The "Investor Trap"

• Ownership Structure: You are buying shares in a structure that provides a contract for potential profits, rather than direct ownership of the underlying Chinese assets. This structure remains subject to the regulatory environment in China.
• One-Man Rule: CEO Jianfei Zhang holds 94% of the voting power. As a minority shareholder, you have no practical say in how the company is governed.
• No Dividends: With over $12 million in debt and no profit, the company is not in a position to pay dividends.

6. Future outlook

The company is currently betting on AI development, but they face a combination of widening losses, accounting challenges, and a restrictive ownership structure. Without a substantial increase in sales, they will likely need to raise additional capital by issuing more shares within the next 6 to 9 months.

---

Investor Takeaway: When reviewing this company, consider whether the potential of their AI project outweighs the risks of their current cash burn, the lack of voting power for minority shareholders, and the ongoing dilution of your investment. If you are looking for stability or income, the current financial data suggests this may not be the right fit for your portfolio.